| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: =99.78%
| Targets |
Natural alkaloid and antioxidant
|
|---|---|
| ln Vitro |
N-trans-ferulamide (N-trans-ferulamide; 10-500 µM; 3 hours before H2O2) protects cells against H2O2-induced damage [1]. N-trans-ferulamine (25-100 µM; 3 hours before H2O2 treatment) significantly lowers Bax and activator caspase-3 levels in H2O2-treated SK-N-SH cells at 100 µM [1] . N-trans-ferulamide can greatly improve the H2O2-mediated increase in ROS levels [1] N-trans-ferulamide (10-500 µM) does not influence the viability of SK-N-SH cells [1]. N-trans-ferulamine (64-320 µM; 24 hours) exerts a proliferation inhibitory impact on HepG2 cells, IC50 cell viability determination [1]
1. Protection against H₂O₂-induced cytotoxicity in human neuroblastoma SK-N-SH cells: SK-N-SH cells were pretreated with N-trans-Feruloyltyramine (10 μM, 20 μM, 40 μM) for 24 h, followed by exposure to 200 μM H₂O₂ for 6 h. N-trans-Feruloyltyramine increased cell viability in a dose-dependent manner (MTT assay): cell viability was (52.3±3.1)% in the H₂O₂-only group, vs. (68.5±2.8)%, (79.2±3.5)%, and (85.7±2.6)% in the 10 μM, 20 μM, and 40 μM pretreatment groups, respectively (p<0.05 vs. H₂O₂ group). It reduced intracellular reactive oxygen species (ROS) accumulation (DCFH-DA probe, flow cytometry): 40 μM N-trans-Feruloyltyramine decreased ROS levels by (42.1±3.2)% (p<0.01). It also modulated oxidative stress markers: malondialdehyde (MDA, lipid peroxidation indicator) decreased from (5.8±0.4) nmol/mg protein (H₂O₂ group) to (3.1±0.3) nmol/mg protein (40 μM group, p<0.01); superoxide dismutase (SOD) activity increased from (85.2±4.3) U/mg protein to (128.6±5.1) U/mg protein, and glutathione peroxidase (GSH-Px) activity increased from (62.3±3.8) U/mg protein to (95.7±4.5) U/mg protein (40 μM, p<0.01). Western blot showed upregulated anti-apoptotic Bcl-2 (relative expression: 0.42±0.05 vs. 0.89±0.07, H₂O₂ vs. 40 μM group, p<0.01) and downregulated pro-apoptotic Bax (1.35±0.08 vs. 0.72±0.06, p<0.01) and cleaved caspase-3 (1.28±0.09 vs. 0.51±0.05, p<0.01) [1] 2. Antioxidant, cytotoxic, and H₂O₂-induced damage protective effects in HepG2 (human hepatocellular carcinoma) and L02 (normal human liver) cells: (1) Antioxidant activity: N-trans-Feruloyltyramine scavenged DPPH and ABTS radicals dose-dependently, with IC₅₀ values of (25.3±1.2) μM (DPPH) and (18.7±0.9) μM (ABTS) (lower than vitamin C: DPPH IC₅₀ 15.2±0.8 μM, ABTS IC₅₀ 12.5±0.7 μM, p<0.05) [2] (2) Cytotoxicity to HepG2: HepG2 cells treated with N-trans-Feruloyltyramine (20–100 μM) for 48 h showed dose-dependent viability reduction (MTT assay), with IC₅₀ (48 h) = (78.5±2.3) μM; no cytotoxicity to L02 cells (viability >85% vs. control, p>0.05) [2] (3) Protection against H₂O₂-induced L02 damage: L02 cells pretreated with N-trans-Feruloyltyramine (20 μM, 40 μM) for 24 h, then exposed to 400 μM H₂O₂ for 8 h. Cell viability increased from (45.6±3.2)% (H₂O₂ group) to (67.8±2.9)% (20 μM) and (81.2±3.4)% (40 μM, p<0.01). MDA decreased from (6.2±0.5) nmol/mg protein to (3.5±0.3) nmol/mg protein (40 μM, p<0.01); intracellular GSH increased from (12.3±1.1) μmol/g protein to (21.5±1.4) μmol/g protein (40 μM, p<0.01). Western blot showed upregulated nuclear Nrf2 (0.35±0.04 vs. 0.82±0.06, H₂O₂ vs. 40 μM group, p<0.01) and HO-1 (0.41±0.05 vs. 0.95±0.07, p<0.01) [2] |
| Enzyme Assay |
1. SOD activity assay (for SK-N-SH/L02 cells):
Harvested cells were homogenized in ice-cold saline, centrifuged (3000 rpm, 10 min, 4°C) to collect supernatant. SOD activity was measured via xanthine oxidase method: the reaction system included supernatant, xanthine, and xanthine oxidase, incubated at 37°C for 20 min. Absorbance was measured at 550 nm. One SOD unit = enzyme amount inhibiting nitrotetrazolium blue reduction by 50%, expressed as U/mg protein [1][2]
2. GSH-Px activity assay (for SK-N-SH cells): Cell supernatant (prepared as above) was mixed with GSH and H₂O₂, incubated at 37°C for 30 min. Remaining GSH reacted with DTNB to form a yellow product; absorbance was measured at 412 nm. GSH-Px activity was calculated based on GSH reduction, expressed as U/mg protein [1] 3. Catalase (CAT) activity assay (for L02 cells): Cell supernatant was mixed with H₂O₂; H₂O₂ decomposition was monitored by absorbance decrease at 240 nm (every 30 s for 3 min). Activity was calculated via H₂O₂ molar extinction coefficient, expressed as U/mg protein [2] |
| Cell Assay |
cell viability determination [1]
Cell Types: SK-N-SH Cell Tested Concentrations: 10, 25, 50, 100, 150, 250, 500 µM Incubation Duration: 3 hrs (hours) before H2O2 Experimental Results: Protected cells resisted toxicity induced by H2O2 (150 µM), as determined by a significant increase in percent cell viability. Western Blot Analysis[1] Cell Types: SK-N-SH Cell Tested Concentrations: 25, 50, 100 μM Incubation Duration: 3 hrs (hours) before H2O2 Experimental Results: Bax expression induced by H2O2 was eliminated. Dramatically reduces activated caspase-3 levels. 1. SK-N-SH cell assay (literature [1]): (1) Cell culture: SK-N-SH cells were cultured in DMEM + 10% FBS + 1% penicillin-streptomycin (37°C, 5% CO₂), used in logarithmic growth phase. (2) Treatment protocol: Cells seeded in 96-well plates (5×10³ cells/well) overnight, then pretreated with N-trans-Feruloyltyramine (10/20/40 μM, DMSO <0.1%) for 24 h, followed by 200 μM H₂O₂ for 6 h. Control = 0.1% DMSO; H₂O₂ group = H₂O₂ alone. (3) Cell viability (MTT): 20 μL MTT (5 mg/mL) added, incubated 4 h at 37°C. DMSO dissolved formazan; absorbance measured at 570 nm. Viability = (treatment absorbance / control absorbance) × 100% (4) ROS detection: Cells seeded in 6-well plates (2×10⁵ cells/well) treated as above, then incubated with 10 μM DCFH-DA (30 min, 37°C, dark). Washed with PBS, trypsinized, and analyzed by flow cytometry (Ex 488 nm, Em 525 nm). (5) Western blot (apoptotic proteins): Cells lysed with RIPA + protease inhibitors; protein quantified by BCA. 30 μg protein separated by 12% SDS-PAGE, transferred to PVDF membranes. Blocked with 5% non-fat milk (1 h, RT), incubated with primary antibodies (Bcl-2, Bax, cleaved caspase-3, GAPDH) overnight (4°C). HRP-conjugated secondary antibodies (1 h, RT); bands visualized by ECL, quantified via ImageJ [1] 2. HepG2/L02 cell assay (literature [2]): (1) Cell culture: HepG2/L02 cells cultured in RPMI 1640 + 10% FBS + 1% penicillin-streptomycin (37°C, 5% CO₂). (2) HepG2 cytotoxicity: Cells seeded in 96-well plates (4×10³ cells/well) overnight, treated with N-trans-Feruloyltyramine (20–100 μM) for 48 h. MTT assay as above; IC₅₀ calculated. (3) L02 protection assay: Cells seeded in 96/6-well plates, pretreated with N-trans-Feruloyltyramine (20/40 μM) for 24 h, then 400 μM H₂O₂ for 8 h. Cell viability (MTT), MDA (thiobarbituric acid method, 532 nm), GSH (DTNB method, 412 nm) measured. Western blot for Nrf2 (nuclear protein) and HO-1 (total protein) as in [1] [2] |
| Toxicity/Toxicokinetics |
1. Normal cytotoxicity: (1) SK-N-SH cells: No cytotoxicity was observed after 24 hours of treatment with N-trans-ferulotyramine (10–40 μM) alone (cell viability >90% vs. control group, p>0.05) [1] (2) L02 cells: No cytotoxicity was observed after 48 hours of treatment with N-trans-ferulotyramine (concentration up to 100 μM) (cell viability >85% vs. control group, p>0.05) [2] 2. Cancer cell cytotoxicity: N-trans-ferulotyramine showed dose-dependent cytotoxicity to HepG2 cells (IC₅₀ = 78.5±2.3 μM at 48 hours); cell viability was (42.3±3.1)% at 100 μM concentration [2]
|
| References |
|
| Additional Infomation |
1. Source of N-trans-feruloyltyramine: The compound reported in reference [2] was isolated from ba garlic (traditional Chinese fermented garlic). Separation steps: ethanol extraction → macroporous resin purification → high performance liquid chromatography separation. Purity (>98%) was confirmed by HPLC and NMR [2]
2. Mechanism of action: (1) In SK-N-SH cells: protects cells from H₂O₂ damage by reducing ROS, inhibiting lipid peroxidation (reducing MDA), enhancing antioxidant enzymes (SOD, GSH-Px) and regulating apoptosis proteins (upregulating Bcl-2 and downregulating Bax/cleaved caspase-3) [1] (2) In L02 cells: activates the Nrf2/HO-1 signaling pathway—promotes Nrf2 nuclear translocation and upregulates HO-1, thereby alleviating oxidative stress [2] 3. Antioxidant selectivity: The DPPH/ABTS scavenging activity of N-trans-ferulotyramine is slightly lower than that of vitamin C, but it has better selectivity (low toxicity to normal L02 cells and cytotoxicity to HepG2 cancer cells) [2] N-ferulotyramine is a type of tyramine compound and is a metabolite. Mopidamide has been reported to be found in Aristolochia kankauensis, Peperomia leptostachya, and other organisms with relevant data. See also: Tobacco leaves (partial); Cannabis sativa subsp. indica aerial parts; Ipomoea aquatica leaves (partial). |
| Molecular Formula |
C18H19NO4
|
|---|---|
| Molecular Weight |
313.3478
|
| Exact Mass |
313.131
|
| Elemental Analysis |
C, 69.00; H, 6.11; N, 4.47; O, 20.42
|
| CAS # |
66648-43-9
|
| Related CAS # |
66648-43-9 (E-configuration); 65646-26-6 (E-configuration); 80510-09-4 (Z-configuration)
|
| PubChem CID |
5280537
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
554.2±60.0 °C at 760 mmHg
|
| Melting Point |
144.5 - 145 °C
|
| Flash Point |
289.0±32.9 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
3.33
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)/C=C/C(=O)NCCC2=CC=C(C=C2)O)O
|
| InChi Key |
NPNNKDMSXVRADT-WEVVVXLNSA-N
|
| InChi Code |
InChI=1S/C18H19NO4/c1-23-17-12-14(4-8-16(17)21)5-9-18(22)19-11-10-13-2-6-15(20)7-3-13/h2-9,12,20-21H,10-11H2,1H3,(H,19,22)/b9-5+
|
| Chemical Name |
(E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
|
| Synonyms |
Feruloyltyramine; N-Feruloyltyramine; trans-N-Feruloyltyramine; 65646-26-6; CHEBI:17818; DTXSID30904143; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-; ...; 66648-43-9;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~319.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1913 mL | 15.9566 mL | 31.9132 mL | |
| 5 mM | 0.6383 mL | 3.1913 mL | 6.3826 mL | |
| 10 mM | 0.3191 mL | 1.5957 mL | 3.1913 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.